Source:http://linkedlifedata.com/resource/pubmed/id/10680643
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2000-3-16
|
| pubmed:abstractText |
Combined thromboxane synthase inhibitors and thromboxane receptors antagonists have been shown to have a beneficial effect on different models of thrombosis in vivo. We studied the action of one of these compounds (DT-TX 30) compared with dazoxiben (a thromboxane synthase inhibitor) on retinal vascularity in streptozotocin-diabetic rats. Ten nondiabetic animals were treated with isotonic saline, 30 (10 animals per group) were given 0.4, 4, and 8 mg kg(-1) per day of DT-TX 30 (p.o.) and 30 (10 animals per group) were given 10, 50, and 100 mg kg(-1) per day of dazoxiben (p.o.) over a 90-day study period. DT-TX 30 caused a dose-dependent decrease of platelet aggregation and thromboxane B2 synthesis. There was an increase of 9, 65, and 166% in the synthesis of prostacyclin after treatment with 0.4, 4, and 8 mg kg(-1) per day, respectively. Retinal vascularity increased in 51, 72, and 182% of animals in response to the three doses used. Synthesis of prostacyclin and the degree of retinal vascularity showed a linear correlation (r2=0.6528,p<0.00001). Dazoxiben, at doses that inhibited thromboxane synthesis as much as DT-TX 30, increased prostacyclin production and retinal vascularity with less potency than DT-TX 30. In conclusion, the antagonism of thromboxane receptors may be an important additional effect to the inhibition of thromboxane synthase in the prevention of ischemic retinal lesions in experimental diabetes.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/6-Ketoprostaglandin F1 alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Chlorobenzenes,
http://linkedlifedata.com/resource/pubmed/chemical/Collagen,
http://linkedlifedata.com/resource/pubmed/chemical/DTTX30,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Thromboxane,
http://linkedlifedata.com/resource/pubmed/chemical/Thromboxane B2,
http://linkedlifedata.com/resource/pubmed/chemical/Thromboxane-A Synthase,
http://linkedlifedata.com/resource/pubmed/chemical/dazoxiben
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0049-3848
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
97
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
125-31
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10680643-6-Ketoprostaglandin F1 alpha,
pubmed-meshheading:10680643-Animals,
pubmed-meshheading:10680643-Blood Glucose,
pubmed-meshheading:10680643-Chlorobenzenes,
pubmed-meshheading:10680643-Collagen,
pubmed-meshheading:10680643-Diabetes Mellitus, Experimental,
pubmed-meshheading:10680643-Diabetic Retinopathy,
pubmed-meshheading:10680643-Enzyme Inhibitors,
pubmed-meshheading:10680643-Imidazoles,
pubmed-meshheading:10680643-Male,
pubmed-meshheading:10680643-Platelet Aggregation,
pubmed-meshheading:10680643-Pyridines,
pubmed-meshheading:10680643-Rats,
pubmed-meshheading:10680643-Rats, Wistar,
pubmed-meshheading:10680643-Receptors, Thromboxane,
pubmed-meshheading:10680643-Retinal Vessels,
pubmed-meshheading:10680643-Thromboxane B2,
pubmed-meshheading:10680643-Thromboxane-A Synthase
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Effect of DT-TX 30, a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on retinal vascularity in experimental diabetes mellitus.
|
| pubmed:affiliation |
Department of Pharmacology and Therapeutics, School of Medicine, University of Málaga, Spain. jpcruz@uma.es
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|